Showing results (141-150 of 176) with videos related to
Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
CtDNA detection with low-pass whole genome bisulfite sequencing in RAS wild-type metastatic colorectal cancer: an exploratory objective of the VALENTINO trialPaolo Manca, Marta Paoli, Francesca Galardi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2025
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate CancerNicole Brighi, Daniel Wetterskog, Osvaldas Vainauskas, et al.The American Journal of Pathology|October 2, 2012
Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic diseaseDolores Di Vizio, Matteo Morello, Andrew C Dudley, et al.Science Translational Medicine|November 6, 2015
Plasma AR and abiraterone-resistant prostate cancerAlessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca, et al.Cancer Letters|March 8, 2022
ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3β dependent Nkx3.1 degradationMarco Lorenzoni, Dario De Felice, Giulia Beccaceci, et al.Cancer Discovery|August 30, 2012
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylationStefan T Börno, Axel Fischer, Martin Kerick, et al.Nature Communications|April 26, 2020
Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypesDeli Liu, Jonathan E Shoag, Daniel Poliak, et al.Cancer Research|January 30, 2014
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancerJohn R Prensner, Wei Chen, Matthew K Iyer, et al.Cancer Discovery|January 10, 2024
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA MethylationGian Marco Franceschini, Orsetta Quaini, Kei Mizuno, et al.Molecular Cancer Therapeutics|January 19, 2012
Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor targetColin C Collins, Stanislav V Volik, Anna V Lapuk, et al.Pageof 18